Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Abxis Co., Ltd. (086890:KRX), powered by AI.
Abxis Co., Ltd. is currently trading at ₩3,530. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Abxis Co., Ltd. on Alpha Lenz.
Abxis Co., Ltd.'s P/E ratio is -13.5.
“Abxis Co., Ltd. trades at a P/E of -13.5 (undervalued) with modest ROE of -9.9%. 3Y revenue CAGR of 11.2% highlights clear growth momentum.”
Ask for details →Abxis Co., Ltd. is a notable entity in the biotechnology and pharmaceuticals sector. Renowned for its innovative approach, the company specializes in the development, manufacturing, and marketing of biotechnological products and pharmaceuticals. Primarily focusing on the creation of therapeutic antibodies, Abxis Co., Ltd. plays a significant role in advancing medical treatments that target specific diseases with precision. The firm's contributions are particularly impactful in areas like oncology and immunology, where targeted therapies can significantly enhance patient outcomes. Situated within a competitive industry landscape, Abxis Co., Ltd.’s strategic partnerships and cutting-edge research initiatives underscore its commitment to addressing global health challenges. Through continuous innovation, Abxis Co., Ltd. not only strengthens its market presence but also aligns with the growing demand for advanced medical solutions, reinforcing its position as a key player in the biotech and pharmaceutical markets.
“Abxis Co., Ltd. trades at a P/E of -13.5 (undervalued) with modest ROE of -9.9%. 3Y revenue CAGR of 11.2% highlights clear growth momentum.”
Ask for details →Abxis Co., Ltd. (ticker: 086890) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $143.9B.
The current price is ₩3,530 with a P/E ratio of -13.48x and P/B of 1.26x.
ROE is -9.92% and operating margin is 2.88%. Annual revenue is $56.7B.